ProPhase Labs, Inc. Disposal Group, Including Discontinued Operation, General and Administrative Expense
ProPhase Labs, Inc. (PRPH) reported Disposal Group, Including Discontinued Operation, General and Administrative Expense of $348.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense · last filed 2019-03-26
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2017-09-30 was $348.00K, a 14.29% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for the quarter ending 2017-03-31 was $348.00K, a 3.26% increase year-over-year.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2017 was $348.00K, a 85.06% decline from fiscal 2016.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2016 was $2.33M, a 50.65% decline from fiscal 2015.
- ProPhase Labs, Inc. disposal group, including discontinued operation, general and administrative expense for fiscal 2015 was $4.72M.
| Period end | Disposal Group, Including Discontinued Operation, General and Administrative Expense 3 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 6 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 9 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 9 month as first filed | Disposal Group, Including Discontinued Operation, General and Administrative Expense 12 month | Disposal Group, Including Discontinued Operation, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $348.00K derived: sum of 2 quarters · filed 2019-03-26 | $348.00K derived: sum of 3 quarters · filed 2019-03-26 | $348.00K 10-K · filed 2019-03-26 | $350.00K 10-K · filed 2018-03-28 | |
| 2017-09-30 | $348.00K 10-Q · filed 2018-11-14 | $348.00K derived: sum of 2 quarters · filed 2018-11-14 | $348.00K 10-Q · filed 2018-11-14 | $1.96M derived: sum of 4 quarters · filed 2018-11-14 | ||
| 2017-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | $348.00K 10-Q/A · filed 2018-08-20 | $1.62M derived: sum of 3 quarters · filed 2018-08-20 | $2.02M derived: sum of 4 quarters · filed 2018-08-20 | ||
| 2017-03-31 | $348.00K 10-Q/A · filed 2018-08-20 | $1.62M derived: sum of 2 quarters · filed 2018-08-20 | $2.02M derived: sum of 3 quarters · filed 2018-08-20 | $2.34M derived: sum of 4 quarters · filed 2018-08-20 | ||
| 2016-12-31 | $1.27M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-08-20 | $1.67M derived: sum of 2 quarters · filed 2018-08-20 | $1.99M derived: sum of 3 quarters · filed 2018-08-20 | $2.33M 10-K/A · filed 2018-08-20 | ||
| 2016-09-30 | $406.00K 10-Q/A · filed 2018-08-20 | $725.00K derived: sum of 2 quarters · filed 2018-08-20 | $1.06M 10-Q/A · filed 2018-08-20 | $1.10M 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $319.00K 10-Q/A · filed 2018-08-20 | $656.00K 10-Q/A · filed 2018-08-20 | ||||
| 2016-03-31 | $337.00K 10-Q/A · filed 2018-08-20 | |||||
| 2015-12-31 | $4.72M 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |